HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced ...

Serina Therapeutics, Inc. ("Serina") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's ...

Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate ...

Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - - Recent third-party clinical data esta ...

So we invent new chemical entities or biologic entities that interfere with a disease process ... But I think we can ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

to develop exercise equipment for Parkinson’s Disease patients in the area. One result of Hunter’s efforts includes a machine ...

Walking as a workout isn't just for the outdoors. Indoors, walking is a beneficial form of physical activity. Find a list of ...

Nearly one million people in the U.S. are living with Parkinson's Disease. Playhouse Square is rolling out a new program to ...

Exercise has been shown to improve brain health and reduce the risk of cognitive decline and dementia over the long-term. But ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product revenue for neffy sales, which reflects revenues from only one week following ...

Clene's cash, cash equivalents and marketable securities totaled $14.6 million as of September 30, 2024, compared to $35.0 million as of December 31, 2023. Clene expects that its resources as of ...